MHRA Drug Safety Update June 2021
- CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases
- Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
- COVID-19 vaccines: updates for June 2021
You can sign up to receive these alerts directly from the MHRA at: MHRA email alerts
Published 23/06/2021. Medicines Update blogs are correct at the time of publication.